STAT June 17, 2024
Hello! Today, we talk about the uptick in physicians using ctDNA to determine if resected cancers are truly gone, we see the FDA offering new guidelines for Covid-19 vaccines, and more.
The need-to-know this morning
- Takeda reported negative results from two Phase 3 studies investigating the use of an experimental drug called soticlestat for the treatment of Dravet syndrome and Lennox-Gastaut syndrome — rare forms of epilepsy. Shares of Ovid Therapeutics, which had licensed soticlestat to Takeda, fell sharply in early trading.
More physicians are using ctDNA tests
Clinicians are increasingly using blood tests that measure circulating tumor DNA, or ctDNA, to figure out whether any cancerous cells remain after a malignancy is removed. One of the most...
Today's Sponsors
Today's Sponsor